Baird raised the firm’s price target on Inspire Medical (INSP) to $236 from $230 and keeps an Outperform rating on the shares. The firm updated its model following Q1 results whwre they announced the INSP V launch which will drive Q2 lower but full year guidance remains unchanged.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSP:
- Inspire Medical price target lowered to $174 from $195 at Wells Fargo
- Inspire Medical Systems: Hold Rating Amid Transition Challenges and Revised Price Target
- Inspire Medical Systems: Strong Financial Performance and Strategic Initiatives Justify Buy Rating
- Inspire Medical Systems Reports Strong Q1 2025 Growth
- Inspire Medical reports Q1 EPS 10c, consensus (23c)